4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights
09 nov. 2023 16h19 HE
|
4D Molecular Therapeutics, Inc.
Rapidly advanced 4D-150 development for wet age-related macular degeneration (wet AMD): completed enrollment of PRISM Phase 2 Dose Expansion nearly two quarters earlier than expected and enrolled...
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFC
01 nov. 2023 16h00 HE
|
4D Molecular Therapeutics, Inc.
Aerosolized 4D-710 was generally well tolerated with no inflammation in any lung biopsy across Cohorts 1 and 2 (1E15 & 2E15 vg; n=7) with up to 17 months follow-upPromising, reproducible, CFTR...
4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease Cardiomyopathy
30 oct. 2023 08h00 HE
|
4D Molecular Therapeutics, Inc.
Initiated single non-human primate (NHP) safety study evaluating intravenous 4D-310 combined with rituximab/sirolimus (R/S) immunosuppressive regimenAmended INGLAXA protocol to minimize risk of...
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 2023 NACFC
25 oct. 2023 08h00 HE
|
4D Molecular Therapeutics, Inc.
4D-710 interim data to be presented in plenary and symposium sessions at the North American Cystic Fibrosis Conference in Phoenix, Arizona held on November 2-4, 2023Company to host webcast on...
4DMT Receives EMA Priority Medicines (PRIME) Designation for 4D-150 Clinical-Stage Genetic Medicine for Treatment of Wet AMD
23 oct. 2023 08h00 HE
|
4D Molecular Therapeutics, Inc.
The European Medicines Agency’s priority medicines status is granted to drug candidates that may offer a major therapeutic advantage over existing treatments or benefit patients without treatment...
4DMT Appoints Uneek Mehra as Chief Financial and Business Officer
12 sept. 2023 16h05 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a clinical-stage biotherapeutics company harnessing the power of directed...
4DMT to Participate in Upcoming Investor Conferences
07 sept. 2023 16h05 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT, 4DMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for...
4DMT Announces First Patient Enrolled in 4D-150 Phase 2 SPECTRA Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in PRISM Clinical Trial in Wet AMD
07 sept. 2023 08h00 HE
|
4D Molecular Therapeutics, Inc.
First patient has been enrolled in the Dose Confirmation stage (n=18) of the Phase 2 SPECTRA clinical trial for intravitreal 4D-150 in patients with diabetic macular edema First patient enrolled in...
4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results and Operational Highlights
09 août 2023 16h05 HE
|
4D Molecular Therapeutics, Inc.
Presented positive interim data from intravitreal 4D-150 Phase 1/2 PRISM clinical trial for patients with wet age-related macular degeneration (wet AMD)Completed target enrollment of 50 patients in...
4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ASRS 2023
29 juil. 2023 12h00 HE
|
4D Molecular Therapeutics, Inc.
Dose response demonstrated in favor of highest tested dose of 3E10 vg/eye, including 100% reduction in supplemental anti-VEGF injections (4 of 4 evaluable patients injection-free) and a clinically...